Connie Matsui Biography and Net Worth

Ms. Matsui brings more than 17 years of general management experience in the biotechnology industry. She retired from Biogen Idec Inc. in January 2009 as the Executive Vice President, Knowledge and Innovation Networks. She served as an Executive Committee member at both Biogen Idec and IDEC Pharmaceuticals, a predecessor of Biogen Idec. She joined IDEC in 1992 and held the positions of Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning; Collaboration Chair for the late stage development and commercialization of rituximab (tradenames: Rituxan^®, MabThera^®) in partnership with Roche and Genentech; and Project Leader for Zevalin^®, the first radioimmunotherapy approved by the FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources. Ms. Matsui serves on the board of directors of Artelo Biosciences, Inc. and Sutro Biopharma, Inc. Ms. Matsui has been active on a number of not-for-profit boards and served as National President/Board Chair of the Girl Scouts of the USA from 1999 to 2002. Ms. Matsui earned B.A. and M.B.A. degrees from Stanford University. She serves as the Chair of the Board of Directors.

What is Connie Matsui's net worth?: The estimated net worth of Connie Matsui is at least $8.38 million as of September 11th, 2020. Ms. Matsui owns 216,753 shares of Halozyme Therapeutics stock worth more than $8,375,336 as of April 19th. This net worth approximation does not reflect any other assets that Ms. Matsui may own. Learn More about Connie Matsui's net worth.
How do I contact Connie Matsui?: The corporate mailing address for Ms. Matsui and other Halozyme Therapeutics executives is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121-1345. Halozyme Therapeutics can also be reached via phone at 858-794-8889 and via email at [email protected]. Learn More on Connie Matsui's contact information.
Has Connie Matsui been buying or selling shares of Halozyme Therapeutics?: Connie Matsui has not been actively trading shares of Halozyme Therapeutics during the last ninety days. Most recently, Connie Matsui sold 32,000 shares of the business's stock in a transaction on Friday, November 5th. The shares were sold at an average price of $40.38, for a transaction totalling $1,292,160.00. Learn More on Connie Matsui's trading history.
Who are Halozyme Therapeutics' active insiders?: Halozyme Therapeutics' insider roster includes Jean-Pierre Bizzari (Director), James Daly (Director), Jeffrey Henderson (Director), Kenneth Kelley (Director), Michael LaBarre (SVP), Nicole Labrosse (CFO), Connie Matsui (Director), Matthew Posard (Director), and Helen Torley (CEO). Learn More on Halozyme Therapeutics' active insiders.
Are insiders buying or selling shares of Halozyme Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 160,000 shares worth more than $6,547,200.00. The most recent insider tranaction occured on April, 17th when SVP Michael J Labarre sold 10,000 shares worth more than $384,900.00. Insiders at Halozyme Therapeutics own 2.4% of the company. Learn More about insider trades at Halozyme Therapeutics.
Information on this page was last updated on 4/17/2024.

Connie Matsui Insider Trading History at Halozyme Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/5/2021	Sell	32,000	$40.38	$1,292,160.00
9/11/2020	Sell	32,000	$27.06	$865,920.00	216,753

Connie Matsui Buying and Selling Activity at Halozyme Therapeutics

Halozyme Therapeutics Company Overview

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Today's Range

Now: $38.64

$37.73

$38.69

50 Day Range

MA: $39.56

$34.64

$41.95

2 Week Range

Now: $38.64

$29.85

$45.00

Volume

1,258,837 shs

Average Volume

1,271,537 shs

Market Capitalization

$4.91 billion

P/E Ratio

18.31

Dividend Yield

N/A

Beta

1.25

Biden’s $374B Giveaway Into This Sector

From DTI | Ad

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story